SCHEMBL2962909

SCHEMBL2962909

CC(C)Nc1ccc(C(=O)NC2CCNCC2)cn1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HCAR3 P49019 1/20 0.55
SSTR5 P35346 1/20 0.53
SMYD3 Q9H7B4 4/20 0.50
HPGDS O60760 2/20 0.49
ALDH1A1 P00352 1/20 0.48
HPGD P15428 1/20 0.48
TSHR P16473 1/20 0.48
PRKAB2 O43741 1/20 0.45
PRKAG1 P54619 1/20 0.45
PRKAA2 P54646 1/20 0.45
PRKAA1 Q13131 1/20 0.45
PRKAG3 Q9UGI9 1/20 0.45
PRKAG2 Q9UGJ0 1/20 0.45
PRKAB1 Q9Y478 1/20 0.45
EGLN1 Q9GZT9 1/20 0.45
TTK P33981 1/20 0.44
TRPV4 Q9HBA0 1/20 0.44
KHK P50053 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2962300 0.86 SMYD3 (0.53) HCAR3SSTR5SMYD3HPGDSALDH1A1
SCHEMBL2960460 0.84 HCAR3 (0.60) HCAR3SMYD3HPGDSALDH1A1HPGD
SCHEMBL2963992 0.78 SMYD3 (0.54) SSTR5SMYD3HPGDSEGLN1KHK
SCHEMBL2964744 0.78 SMYD3 (0.54) SMYD3HPGDSALDH1A1EGLN1KHK
SCHEMBL2952214 0.77 SSTR5 (0.55) SSTR5ALDH1A1
SCHEMBL12089754 0.74 SMYD3 (0.50) SMYD3HPGD
SCHEMBL14190691 0.73 HPGDS (0.62) SMYD3HPGDSPRKAB2PRKAG1PRKAA2
SCHEMBL2955276 0.72 SSTR5 (0.71) SSTR5HPGDPRKAB2PRKAG1PRKAA2
SCHEMBL279571 0.72 RAB9A (0.71) SMYD3ALDH1A1HPGD
SCHEMBL23619440 0.72 HPGD (0.56) HCAR3ALDH1A1HPGDTSHRTRPV4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7772253-B2 Amide derivatives as somatostatin receptor 5 antagonists HOFFMAN-LA ROCHE INC. (US) 2010-08-10 US disclosed
EP-1893603-B1 PIPERIDIN-4-YL-AMIDE DERIVATIVES AND THEIR USE AS SST RECEPTOR SUBTYPE 5 ANTAGONISTS HOFFMANN LA ROCHE (CH) 2009-10-14 EP disclosed
EP-1893603-A1 PIPERIDIN-4-YL-AMIDE DERIVATIVES AND THEIR USE AS SST RECEPTOR SUBTYPE 5 ANTAGONISTS F. Hoffmann-La Roche AG (CH) 2008-03-05 EP disclosed
WO-2006128803-A1 PIPERIDIN-4-YL-AMIDE DERIVATIVES AND THEIR USE AS SST RECEPTOR SUBTYPE 5 ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2006-12-07 WO disclosed
US-20060276508-A1 Amide derivatives as somatostatin receptor 5 antagonists F. HOFFMANN-LA ROCHE AG (CH) 2006-12-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276508-A1 Amide derivatives as somatostatin receptor 5 antagonists SSTR5, SSTR3, SSTR1 HCAR3 85/4885SSTR5 1/4885SMYD3 2731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.